-

Eurofins Develops Most Comprehensive COVID-19 Testing Network in the UK to Enable International Travel

LUXEMBOURG--(BUSINESS WIRE)--Easy, reliable, high-quality and cost-effective testing for SARS-CoV-2 (COVID-19), in compliance with local regulatory requirements, is crucial to enabling millions of passengers to complete their journeys in comfort and safety. Eurofins has rapidly developed a network of 67 sampling stations across the UK, expected to grow to 100 stations throughout July, combined with a nationwide at-home PCR test kit offering and 103 drop box stations across the UK for sample collection. This is the largest and most comprehensive solution for COVID-19 testing in the UK. and complements Eurofins’ rapidly developed network of 500 testing centres across Europe, facilitating testing for UK travellers at European destinations. Eurofins expects to have established 1,000 centres across Europe by July.

Eurofins’ network of testing centres in the UK covers major travelling hubs and provides testing accessibility in a broad variety of locations such as hotels, event and conference centres and travel agents, improving customer proximity and ease of testing. Eurofins is on the Government’s approved list of COVID-19 testing service providers for Day 2, Day 5 and Day 8 testing.

The combined resources of 4 Eurofins laboratories in the UK will process COVID-19 PCR tests. Results are provided electronically, and can also be delivered alongside a travel certificate, for those needing to make international journeys.

The home test kits can be delivered to hotels, self-isolation locations and quarantine addresses, and can be used in support of the international traveller’s requirements in each of the nations in the UK.

Further information on Eurofins’ COVID-19 testing services in the UK can be found here.

To further support testing, in particular for European travel this summer, Eurofins has created an intuitive web-portal for travelers to book testing appointments and access their testing information, not only in their country of origin, but also at destination locations. All of Eurofins’ testing centres, including those in the UK, are listed on a single landing page, identifying nearby testing locations. This portal is available in 12 languages; https://www.eurofins.com/covid19-travel-regulations-testing-stations/

Eurofins is committed to offering the best possible testing services to all travellers looking for a seamless, comfortable and safe travel experience. Eurofins has also invested in laboratory capacity and IT solutions that will ensure fast turn-around times for test results (as low as a few hours from receipt of sample at the laboratory for gold standard PCR Tests) and has facilitated 25 million PCR tests to date in its own laboratories. Alongside Eurofins’ home-testing offering (where supported by Health Authorities), the Group’s extensive testing centres and mobile sample facilities enable Eurofins to offer an easy and comprehensive experience for international travellers across Europe and the world.

For more information, please visit https://www.eurofins.com/eurofins-safer-work-covid-19-solutions/

Notes to editor:

About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. With over 50,000 staff across a network of more than 800 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.

Eurofins Shares are listed on Euronext Paris Stock Exchange.

Eurofins

BOURSE:ERF

Release Versions

More News From Eurofins

Eurofins Scientific SE: Weekly Report on Share Repurchases From 09th March to 13th March 2026

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins (Paris:ERF): Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 09/03/2026 FR0014000MR3 10 000 63.1848 CEUX EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 09/03/2026 FR0014000MR3 30 000 63.1292 XPAR EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 10/0...

Eurofins Biomnis Launches New Clinical LC‑MS/MS Method for the Detection of Cereulide Toxin in Stool Samples

LYON, France--(BUSINESS WIRE)--Eurofins Biomnis, a leading European provider of specialised clinical diagnostics services, and part of the global network of Eurofins laboratories, announces the successful development and validation of a new liquid chromatography tandem mass spectrometry (LC‑MS/MS) method for the detection and quantification of cereulide toxin in human stool samples. This innovation underlines Eurofins Biomnis’ diagnostic innovation, and its commitment to contributing its expert...

Eurofins Scientific SE: Weekly Report on Share Repurchases from 02nd March to 06th March 2026

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (Paris:ERF): Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 02/03/2026 FR0014000MR3 30 000 67.7739 XPAR EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 02/03/2026 FR0014000MR3 10 000 67.7248 CEUX EUROFINS SCIENTIFIC 529900JEHFM...
Back to Newsroom